JBIO
- GlobeNewswire
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy Phase 2 JADE101 clinical trial in IgA ...
- GlobeNewswire
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
SAN FRANCISCO and VANCOUVER, British Columbia, June 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the "Company" or "Jade") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on ...
- Analyst Upgrades
UBS Initiates Coverage On Jade Biosciences with Buy Rating, Announces Price Target of $45
UBS analyst Michael Yee initiates coverage on Jade Biosciences with a Buy rating and announces Price Target of $45. ...
- GlobeNewswire
Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO and VANCOUVER, British Columbia, June 05, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing ...
- GlobeNewswire
Jade Biosciences Announces Pricing of Public Offering of Common Stock
SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing ...
- GlobeNewswire
Jade Biosciences Announces Proposed Underwritten Public Offering
SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing ...
- Analyst Upgrades
Wedbush Maintains Outperform on Jade Biosciences, Raises Price Target to $45
Wedbush analyst Laura Chico maintains Jade Biosciences with a Outperform and raises the price target from $34 to $45. ...
- Analyst Upgrades
BTIG Maintains Buy on Jade Biosciences, Raises Price Target to $74
BTIG analyst Julian Harrison maintains Jade Biosciences with a Buy and raises the price target from $39 to $74. ...
- Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Jade Biosciences, Raises Price Target to $55
HC Wainwright & Co. analyst Arthur He maintains Jade Biosciences with a Buy and raises the price target from $45 to $55. ...
- GlobeNewswire
Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy
~70% IgA reductions sustained at 12 weeks after a single dose of JADE101>70% IgA reductions projected at steady state with a single subcutaneous maintenance injection every 12 weeksIgA-lowering effect observed to be ...
- GlobeNewswire
Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy
SAN FRANCISCO and VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the "Company" or "Jade") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class ...
- Analyst Upgrades
BTIG Reiterates Buy on Jade Biosciences, Maintains $39 Price Target
BTIG analyst Julian Harrison reiterates Jade Biosciences with a Buy and maintains $39 price target. ...
- GlobeNewswire
Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody
Interim Phase 1 data in rheumatoid arthritis expected in 2027 are anticipated to inform indication prioritization across multiple potential autoimmune indications supported by BAFF-R biology JADE201 preclinical data ...
- GlobeNewswire
Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy
Interim Phase 2 JADE101 data are expected in 2027 SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the "Company" or "Jade") (NASDAQ:JBIO), a clinical-stage ...
- Analyst Upgrades
Guggenheim Maintains Buy on Jade Biosciences, Raises Price Target to $32
Guggenheim analyst Vamil Divan maintains Jade Biosciences with a Buy and raises the price target from $23 to $32. ...
- Analyst Upgrades
Wedbush Maintains Outperform on Jade Biosciences, Raises Price Target to $34
Wedbush analyst Laura Chico maintains Jade Biosciences with a Outperform and raises the price target from $24 to $34. ...
- GlobeNewswire
Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
Interim biomarker-rich Phase 1 data for JADE101 to be featured in an oral session at the 63rd European Renal Association Congress Phase 2 trial of JADE101 in IgA nephropathy patients expected to begin in the second ...
- Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Jade Biosciences, Raises Price Target to $45
HC Wainwright & Co. analyst Arthur He maintains Jade Biosciences with a Buy and raises the price target from $35 to $45. ...
- GlobeNewswire
Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO and VANCOUVER, British Columbia, April 23, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing ...
- GlobeNewswire
Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer
SAN FRANCISCO and VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing ...
- Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Jade Biosciences, Raises Price Target to $35
HC Wainwright & Co. analyst Arthur He maintains Jade Biosciences with a Buy and raises the price target from $25 to $35. ...
- Analyst Upgrades
BTIG Maintains Buy on Jade Biosciences, Raises Price Target to $39
BTIG analyst Julian Harrison maintains Jade Biosciences with a Buy and raises the price target from $28 to $39. ...
- Analyst Upgrades
Guggenheim Maintains Buy on Jade Biosciences, Raises Price Target to $23
Guggenheim analyst Vamil Divan maintains Jade Biosciences with a Buy and raises the price target from $17 to $23. ...
- Analyst Upgrades
Wedbush Reiterates Outperform on Jade Biosciences, Maintains $24 Price Target
Wedbush analyst Laura Chico reiterates Jade Biosciences with a Outperform and maintains $24 price target. ...
- GlobeNewswire
Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy expected to begin mid-2026 with preliminary data anticipated in 2027JADE201, ...